Stock Researching

FDA Approves Abraxane For Treatment Of Pancreatic Cancer

Stock Researching
Publish date: Tue, 10 Sep 2013, 09:59 AM
Stock Researching
0 252,468
Stockresearching is a blog designed to help the independent investor create new ideas and receive valuable informed information.
Following Message

From Liston Street Pulse:

Abraxane in combination with gemcitabine was approved by the FDA on September 9, 2013 as a first-line treatment for late-stage metastatic pancreatic cancer. Earlier, in January this year, Celgene (CELG) had presented late stage clinical data at symposium of the American Society of Clinical Oncology. Data presented by the company demonstrated […]

The post FDA Approves Abraxane For Treatment Of Pancreatic Cancer appeared first on Liston Street Pulse.

More articles on Stock Researching
Visa Inc: Inside the Numbers 2016 $V

Created by Stock Researching | Dec 17, 2016

Enbridge Inc: 2016 Fundamental Analysis WACC, Cost of Debt and Cost of Equity $ENB

Created by Stock Researching | Dec 13, 2016

Apple Inc: DCF Calculation Apple Inc. $AAPL

Created by Stock Researching | Dec 10, 2016

Apple Inc: Fundamental Analysis WACC, Cost of Debt and Cost of Equity $AAPL

Created by Stock Researching | Dec 04, 2016

Visa Inc: DCF Calculation Visa Inc. $V

Created by Stock Researching | Dec 03, 2016

Visa Inc: Fundamental Analysis WACC, Cost of Debt and Cost of Equity $V

Created by Stock Researching | Dec 02, 2016

Telus Corp. Cost of Debt, CAPM, WACC and Valuation $TU, $T.TO

Created by Stock Researching | Nov 19, 2016

Assessing Canadian Telecom Exposure, $BCE is worth a look

Created by Stock Researching | Nov 10, 2016

J&J Current Valuation. Is This The Time To Buy? $JNJ

Created by Stock Researching | Sep 17, 2016

$UPS Deriving Value From E-Commerce Growth And Lower Energy Prices

Created by Stock Researching | Oct 05, 2015

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment